Art. 2 Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…

Definitions

In forcecited 14×
1.

In addition to the definitions laid down in Article 1 of Directive 2001/83/EC and in Article 3, points (a) to (l) and (o) to (q) of Directive 2004/23/EC, the following definitions shall apply for the purposes of this Regulation:

(a)

‘Advanced therapy medicinal product’ means any of the following medicinal products for human use:

a gene therapy medicinal product as defined in Part IV of Annex I to Directive 2001/83/EC,

a somatic cell therapy medicinal product as defined in Part IV of Annex I to Directive 2001/83/EC,

a tissue engineered product as defined in point (b).

(b)

‘Tissue engineered product’ means a product that:

contains or consists of engineered cells or tissues, and

is presented as having properties for, or is used in or administered to human beings with a view to regenerating, repairing or replacing a human tissue.

A tissue engineered product may contain cells or tissues of human or animal origin, or both. The cells or tissues may be viable or non-viable. It may also contain additional substances, such as cellular products, bio-molecules, bio-materials, chemical substances, scaffolds or matrices.

Products containing or consisting exclusively of non-viable human or animal cells and/or tissues, which do not contain any viable cells or tissues and which do not act principally by pharmacological, immunological or metabolic action, shall be excluded from this definition.

(c)

Cells or tissues shall be considered ‘engineered’ if they fulfil at least one of the following conditions:

the cells or tissues have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved. The manipulations listed in Annex I, in particular, shall not be considered as substantial manipulations,

the cells or tissues are not intended to be used for the same essential function or functions in the recipient as in the donor.

(d)

‘Combined advanced therapy medicinal product’ means an advanced therapy medicinal product that fulfils the following conditions:

it must incorporate, as an integral part of the product, one or more medical devices within the meaning of Article 1(2)(a) of Directive 93/42/EEC or one or more active implantable medical devices within the meaning of Article 1(2)(c) of Directive 90/385/EEC, and

its cellular or tissue part must contain viable cells or tissues, or

its cellular or tissue part containing non-viable cells or tissues must be liable to act upon the human body with action that can be considered as primary to that of the devices referred to.

2.

Where a product contains viable cells or tissues, the pharmacological, immunological or metabolic action of those cells or tissues shall be considered as the principal mode of action of the product.

3.

An advanced therapy medicinal product containing both autologous (emanating from the patient himself) and allogeneic (coming from another human being) cells or tissues shall be considered to be for allogeneic use.

4.

A product which may fall within the definition of a tissue engineered product and within the definition of a somatic cell therapy medicinal product shall be considered as a tissue engineered product.

5.

A product which may fall within the definition of:

a somatic cell therapy medicinal product or a tissue engineered product, and

a gene therapy medicinal product,

shall be considered as a gene therapy medicinal product.

The 10 that are cited most themselves, of 14.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…Law

    … à base d'hybridomes et d'anticorps monoclonaux. 1 bis. Médicaments de thérapie innovante, tels que définis à l’article 2 du règlement (CE) no 1394/2007 du Parlement européen et du Conseil du 13 novembre 2007 concernant les …

  • Directive (EU) 2001/831Law

    … продукти за модерна терапия, по смисъла на определението от член 2, параграф 1, буква а) от Регламент (ЕО) № 1394/2007, се следват …

  • Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…2Law

    … лекарствен продукт за модерна терапия съгласно определението в член 2, параграф 1, буква а) от Регламент (ЕО) № 1394/2007 на Европейския …

  • Code de la santé publiquel1124-1l4211-9-2l5121-1-1l5121-1-2Law

    … 1121-13. Les essais cliniques de médicaments de thérapie innovante tels que définis à l'article 2 du règlement (CE) n° 1394/2007 du Parlement européen et du Conseil, du 13 novembre 2007, concernant les médicaments de thérapie …

  • The Human Medicines Regulations 2012Law

    … 167 of the Human Medicines Regulations 2012. Part IV, paragraph 1, first paragraph | The reference to “point (a) of Article 2(1) of Regulation (EC) No 1394/2007” is to be read as a reference to regulation 2A of the Human Medicines …

  • The Human Medicines (Amendment etc.) (EU Exit) Regulations 20191Law

    … 167 of the Human Medicines Regulations 2012. Part IV, paragraph 1, first paragraph | The reference to “point (a) of Article 2(1) of Regulation (EC) No 1394/2007” is to be read as a reference to regulation 2A of the Human Medicines …

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…Law

    … mammalian cells, hybridoma and monoclonal antibody methods. 1a. Advanced therapy medicinal products as defined in Article 2 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced …

  • Code de la sécurité socialel162-16-6Law

    … 162-22-7 et L. 162-23-6, de traitement par des médicaments de thérapie innovante définis à l'article 2 du règlement (CE) n° 1394/2007 du Parlement européen et du Conseil du 13 novembre 2007 concernant les médicaments de thérapie …

  • Gewebesicherheitsgesetz2Law

    … zuletzt geändert durch die Richtlinie 2004/27/EG sowie biotechnologisch bearbeitete Gewebeprodukte gemäß Artikel 2 Abs. 1 lit. b der Verordnung (EG) Nr. 1394/2007 des Europäischen Parlaments und des Rates vom 13. November 2007 über …

  • Directive (EU) 2009/120Law

    … продукти за модерна терапия, по смисъла на определението от член 2, параграф 1, буква а) от Регламент (ЕО) № 1394/2007, се следват …